Clinical Trial

ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis

Study acronym: EVERLAST-A
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-07-21; most recent amendment 2026-06-30.
Status change: Recruiting → Active, Not Recruiting 2026-03-15
Trial Details
NCT Number NCT07090330
Lead Sponsor Oruka Therapeutics, Inc.
Conditions Plaque Psoriasis
Enrollment 80 participants
Start Date 2025-07-18
Primary Completion 2026-03-25 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-01